Browsing Category
Featured Articles
FDA Advises Sarepta to Lift Pause and Resume ELEVIDYS Shipments for Ambulatory Duchenne Patients
Sarepta Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has informed the company it may lift its voluntary pause on shipments of ELEVIDYS (delandistrogene…
Read More...
Read More...
Boehringer Ingelheim and Re-Vana Partner to Develop Long-Acting Eye Disease Therapies
Boehringer Ingelheim and Re-Vana Therapeutics, a US- and UK-based developer of ocular drug delivery technologies, have announced a strategic collaboration and licensing agreement aimed…
Read More...
Read More...
GSK and Hengrui Pharma Partner to Develop Up to 12 Innovative Medicines in Key Therapeutic Areas
GSK plc has announced a major strategic collaboration with Hengrui Pharma, aimed at developing up to 12 innovative medicines across Respiratory, Immunology & Inflammation…
Read More...
Read More...
Gilead’s Twice-Yearly Lenacapavir Gets Positive CHMP Opinion for HIV Prevention
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending…
Read More...
Read More...
EU Regulators Back Alhemo Label Expansion for Haemophilia A and B Without Inhibitors
Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending an expanded label for Alhemo…
Read More...
Read More...
Solid Biosciences Earns FDA Fast Track for SGT-501 Gene Therapy in CPVT
Solid Biosciences Inc., a clinical-stage company focused on genetic medicines for neuromuscular and cardiac diseases, announced it has received Fast Track designation from the U.S. Food…
Read More...
Read More...
Gefurulimab Shows Significant Improvement in Daily Function for gMG Patients in Phase III PREVAIL…
A new potential treatment for generalised myasthenia gravis (gMG), a rare and debilitating autoimmune neuromuscular disease, has shown promising results in a large international…
Read More...
Read More...
Sanofi to Acquire Vicebio, Boosting Respiratory Vaccine Portfolio
Sanofi has announced an agreement to acquire London-based biotechnology company Vicebio Ltd, expanding its presence in the respiratory vaccine space. The deal brings with it a promising…
Read More...
Read More...
AstraZeneca to Invest $50 Billion in U.S. for Drug Manufacturing and R&D
AstraZeneca announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected…
Read More...
Read More...
Astellas Partners with Korea’s KISED to Support Drug-Discovery Startups
Astellas Pharma Inc. announced the signing of a memorandum of understanding (MoU) with the Korea Institute of Startup and Entrepreneurship Development (KISED), a government-backed…
Read More...
Read More...
ENHERTU Plus Pertuzumab Granted U.S. Breakthrough Therapy Status for HER2+ Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ENHERTU (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab for the…
Read More...
Read More...
Sanofi’s SAR446597 Granted FDA Fast Track for Geographic Atrophy in AMD
The U.S. Food and Drug Administration (FDA) has granted fast track designation to SAR446597, a one-time intravitreal gene therapy developed by Sanofi for the treatment of geographic…
Read More...
Read More...
FDA Approves GSK’s Shingrix in Prefilled Syringe Format
GSK announced that the U.S. Food and Drug Administration (FDA) has approved a new prefilled syringe presentation of Shingrix, the company’s vaccine for the prevention of shingles…
Read More...
Read More...
Boehringer Ingelheim and LEO Pharma Partner to Commercialize and Develop SPEVIGO
Boehringer Ingelheim and LEO Pharma have entered an exclusive global license and transfer agreement to commercialize and further develop SPEVIGO (spesolimab), a monoclonal antibody…
Read More...
Read More...
Merck to Acquire Verona Pharma, Adding First-in-Class COPD Drug Ohtuvayre to Pipeline
Merck, known as MSD outside the U.S. and Canada, announced that it will acquire Verona Pharma plc in a $10 billion deal, strengthening its presence in the respiratory disease space. The…
Read More...
Read More...
AbbVie and IGI Ink Global Deal for First-in-Class Trispecific Antibody ISB 2001
AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI),announced an exclusive licensing agreement for IGI's lead…
Read More...
Read More...
GSK Completes Acquisition of Efimosfermin to Combat Steatotic Liver Disease
GSK plc has finalized its acquisition of efimosfermin alfa from Boston Pharmaceuticals, a promising investigational therapy targeting steatotic liver disease (SLD). Efimosfermin is a…
Read More...
Read More...
FDA Grants Priority Review for WINREVAIR Label Update Following ZENITH Trial Results
Merck, known as MSD outside the U.S. and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental Biologics License…
Read More...
Read More...
Lynozyfic (linvoseltamab-gcpt) Granted FDA Accelerated Approval for Relapsed/Refractory Multiple…
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic (linvoseltamab-gcpt) to treat adult patients…
Read More...
Read More...
Vetter Breaks Ground on New Clinical Site
Vetter, a leading, globally operating Contract Development and Manufacturing Organization (CDMO), celebrated the start of construction for its new clinical manufacturing site in Des…
Read More...
Read More...
